Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

An update on the PASHION study, which is currently in the process of setting up.

PASHION logo

PASHiOn will be the first non-industry funded knee device study run out of SITU, the surgical trials theme leads in OCTRU.

Having run several orthopaedic trials for late stage OA (osteoarthritis), we are keen to explore preventative and possible restorative treatment for earlier stage OA. The trial will assess whether personalised digitally planned High Tibial Osteotomy (HTO), with custom 3D printed patient specific surgical guides and plate, produces a more accurate correction and results in better outcomes compared to standard HTO performed with a “one-size fits all” plate.

Similar stories

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

Liposomal bupivacaine found to be no more effective than current treatments for post-operative knee pain

A new study published in JAMA, has found that a drug recently licensed in the UK has no effect on post-operative knee replacement recovery or pain, compared to the current treatment when administered at site of surgery.

Cemented hip replacement improves quality of life for patients over 60

The White 5 trial compared implants fixed with bone cement against uncemented implants for hip fractures treated with hemiarthroplasty.

FUTURE-GB looking ahead to 2022

FUTURE-GB has bounced into 2022 ahead of both predicted recruitment into Stage 2 (the Randomised Controlled Trial), and the sites open in Stage 2! Congratulations to all our sites for their hard work so far.